Compare HP Inc (HPQ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Neurocrine Biosciences Inc — how do they compare? HP Inc trades at $28.57 (market cap $26.59B), while Neurocrine Biosciences Inc trades at $158.46 (market cap $16.46B). The key difference: HP Inc is the larger of the two by market cap, and HP Inc pays a 4.13% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| HPQ | NBIX | |
|---|---|---|
Market Cap | $26.59B | $16.46B |
Sector | Technology | Health |
52-Week High | $30.05 | $185.50 |
52-Week Low | $18.20 | $123.10 |
Enterprise Value | $33.75B | $16.48B |
Dividend Yield | 4.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $29.80, down 0.83% on the day, with a bullish technical signal supported by moving averages and positive earnings beats in recent quarters. The company reported Q2 2026 revenue of $14.4B and EPS of $0.86, exceeding expectations, driven by premium product mix and AI-driven efficiencies. Valuation metrics show a P/E of 10.77 and P/S of 0.48, indicating potential undervaluation relative to historical averages.
The outlook remains positive with continued earnings momentum and a 2026 revenue forecast of $57.4B, though risks include PC market volatility and competitive pressures. Analyst consensus is mixed with 29% buy ratings, but technical support at $29 suggests near-term stability. The dividend yield of approximately 4% provides income appeal amid growth initiatives.
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
